Type Condition

Omaha, NE

179 Clinical Paid Trials near Omaha, NE

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

CF33-CD19 + Blinatumomab for Solid Cancers

Omaha, Nebraska
This trial tests a new virus and an immune-boosting drug in adults with advanced cancers that haven't responded to other treatments. The virus aims to kill cancer cells directly, while the drug helps the immune system attack the cancer.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

50 Participants Needed

SC291 for B-Cell Malignancies

Omaha, Nebraska
This trial tests SC291, a new drug for blood cancers, in patients with NHL or CLL who have tried multiple treatments. SC291 is given after chemotherapy to better target cancer cells.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

16 Participants Needed

Reverberation Impact on Spatial Hearing Development

Omaha, Nebraska
The goal of the clinical trial study (Phase 0) is to map out the developmental trajectory of functional spatial hearing abilities in reverberant environments for children with normal hearing between the ages of 6 and 18 years, and to understand the inter-relationships between the three perceptual abilities: auditory object size formation, spatial acuity, and spatial unmasking during typical development. Children are asked to perform psychoacoustic tasks when the auditory stimuli are processed to present in virtual acoustic environments (1) with no reverberation and (2) with one of the two levels of reverberation that emulate everyday indoor environments. The intervention of this clinical study is in the random assignment of one of the two reverberant environments. Researchers will compare these children with a group of normal-hearing adults to anchor matured performances.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:6 - 30

120 Participants Needed

PCI-24781 + Temozolomide for Recurrent Brain Cancer

Omaha, Nebraska
Glioblastoma (GBM), WHO grade IV glioma, represents the majority of adult malignant primary brain tumors, with an incidence of 2-3 per 100,000 person-years. The survival for GBM has increased in the last decade but is still low with a median survival of 15-18 months. Recurrence after initial standard therapy, radiation therapy and chemotherapy with temozolomide, few options are available. Even with further therapy, median progression free survival at 6 months after first relapse (PFS-6) is only 15%. Similarly, anaplastic astrocytoma and anaplastic oligodendroglioma, grade III gliomas, once recurrent after radiation therapy and first-line chemotherapy, have identical therapeutic options and poor outcomes with PFS-6 of 31%. Temozolomide (TMZ) has a favorable side effect profile and is available orally, however, cytotoxicity occurs. Metronomic temozolomide at low doses on a continuous schedule, have demonstrated better survival in studies. This study will determine the recommended dose and the side effects of PCI-24781/Abexinostat with metronomic temozolomide.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:19+

24 Participants Needed

MYTX-011 for Lung Cancer

Omaha, Nebraska
This trial is testing MYTX-011, a new medication that targets advanced lung cancer cells with specific genetic markers. It uses an antibody to guide a powerful drug directly to the cancer cells to kill them.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

250 Participants Needed

Bridging Radiation Therapy for Lymphoma

Omaha, Nebraska
The goal of this clinical trial is to learn about treatment for people with B-cell lymphoma that did not respond to treatment or that has gotten worse after treatment. The aim of this trial is to answer the following questions: * If it is realistic to give people radiation treatment before they receive a chimeric antigen receptor (CAR) T-cell treatment for their cancer * If it is safe to give people radiation treatment before they receive a CAR T-cell treatment for their cancer
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:19+

33 Participants Needed

Psilocybin for Psychological Distress in Pancreatic and Biliary Tract Cancer

Omaha, Nebraska
This trial is testing a psilocybin-based treatment to help patients with inoperable pancreas or biliary tract cancers feel less distressed. Psilocybin, found in certain mushrooms, can change brain activity to improve mood and reduce anxiety. The study will also look at how this treatment affects patients' families. Psilocybin has been historically used for ritualistic, recreational, and medicinal purposes, with recent studies recognizing its potential to treat depression and anxiety.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:19 - 85

24 Participants Needed

CPI-818 for T-Cell Lymphoma

Omaha, Nebraska
This trial is testing a new pill called CPI-818 for patients with T-cell lymphoma that hasn't responded to other treatments. The pill works by blocking a protein that helps cancer cells grow.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

151 Participants Needed

ONC201 Maintenance Therapy for Acute Myeloid Leukemia

Omaha, Nebraska
This is a single-center pilot study of 20 patients with AML/MDS. Eligible patients will be enrolled following an informed consent between 6-20 weeks after allogeneic hematopoietic stem cell transplant. Patients will receive weekly oral ONC 201 for a total of 52 weeks.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:19+

20 Participants Needed

Vabomere for Pediatric Bacterial Infections

Omaha, Nebraska
A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:< 17

39 Participants Needed

Oritavancin for Bacterial Infections in Children

Omaha, Nebraska
The purpose of this Phase 1 trial is to evaluate the pharmacokinetics, safety and tolerability of oritavancin in patients \<18 years old with a confirmed or suspected bacterial infection.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:< 18

41 Participants Needed

AZD2284 for Prostate Cancer

Omaha, Nebraska
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Sex:Male

134 Participants Needed

ACE-232 for Prostate Cancer

Omaha, Nebraska
This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Sex:Male

67 Participants Needed

Azer-cel for Autoimmune Disease

Omaha, Nebraska
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 60

32 Participants Needed

EBV Vaccine for Healthy Adults

Omaha, Nebraska
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 30

200 Participants Needed

V540B Vaccine for HPV Prevention

Omaha, Nebraska
Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For some people, HPV infections can last longer and may cause cancer years later. A standard vaccine to prevent HPV-related cancers is GARDASIL®9 (G9). G9 protects against 9 types of HPV but it does not protect against other types of HPV. The study vaccine (called V540B) is designed to protect against the same HPV types that G9 protects against plus other HPV types. The main goal of this study is to learn about the safety of V540B in healthy adults and if people tolerate it.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 45

72 Participants Needed

BTX-9341 + Fulvestrant for Breast Cancer

Omaha, Nebraska
The purpose of this study is to test BTX-9341 alone or in combination with fulvestrant (a currently marketed medication for breast cancer) in participants with advanced and/or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The study includes a dose escalation part (Part A) where small groups of participants will receive increasing doses of BTX-9341 or BTX-9341 + fulvestrant followed by a dose expansion part (Part B) where participants will receive the dose of BTX-9341 selected in Part A + fulvestrant.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

82 Participants Needed

AMG 193 + Other Therapies for Pancreatic Cancer

Omaha, Nebraska
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

188 Participants Needed

FT819 for Lupus

Omaha, Nebraska
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate to severe active systemic lupus erythematosus (SLE), antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:12 - 70

244 Participants Needed

Elranatamab + Iberdomide for Multiple Myeloma

Omaha, Nebraska
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma. Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disease or condition that does not respond to treatment. Relapsed means the return of a disease after a period of improvement. All study medicines are given in cycles that last 28 days. Everyone taking part in this study will receive elranatamab as a shot under the skin. Iberdomide will be taken by mouth once a day for 21 days over a 28-day cycle. Participants will receive study medicine until: * their disease progresses or, * they experience unacceptable side effects or, * they choose to no longer take part in the study. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and can be used for multiple myeloma treatment.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

87 Participants Needed

Why Other Patients Applied

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

Novel Drug Combinations for Multiple Myeloma

Omaha, Nebraska
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

111 Participants Needed

Oral EGFR Inhibitor for Lung Cancer

Omaha, Nebraska
This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSCLC patients with EGFR exon 20 insertion mutations，uncommon mutations, classical mutations (Ex19del and L858R), and drug-resistant mutation (T790M). Patients will be enrolled and dosed according to the most current protocol. This study is made of two Parts. Part 1 includes a dose escalation into 7 cohorts and patient allocation to these cohorts will be via slot allocation. Each cohort has a minimum of 3 and a maximum of 6 patients for a total of 21 - 42 patients. The patient population of the dose escalation phase will include patients with advanced NSCLC harboring EGFR classical mutations or Ex20ins mutations, or uncommon mutations. Part 2 includes an expansion phase and the expansion phase will explore one or more dose levels of PLB1004 in NSCLC patients with EGFR Ex20ins mutations, classical mutations, or uncommon mutations.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

81 Participants Needed

Ziftomenib Combinations for Acute Myeloid Leukemia

Omaha, Nebraska
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

171 Participants Needed

FT522 + Rituximab for B-Cell Lymphoma

Omaha, Nebraska
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

166 Participants Needed

CC-97540 for Severe Refractory Lupus

Omaha, Nebraska
This trial is testing a new drug called CC-97540. It aims to help people with severe autoimmune diseases that don't get better with regular treatments. Researchers want to see if the drug is safe, how it moves through the body, and if it can improve patients' health.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

144 Participants Needed

AV-380 for Cachexia

Omaha, Nebraska
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

30 Participants Needed

mRNA EBV Vaccine for EBV Infection

Omaha, Nebraska
This trial tests the safety of a new vaccine called mRNA-1195 in healthy adults. The study is split into two parts based on whether participants have been exposed to Epstein-Barr Virus. The vaccine works by teaching the body to recognize and fight the virus.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55

474 Participants Needed

RYZ101 + Standard Treatments for Small Cell Lung Cancer

Omaha, Nebraska
This trial is testing a new drug, RYZ101, combined with standard cancer treatments in patients with a specific type of untreated lung cancer. The new drug aims to target certain receptors on cancer cells, while the other drugs work to kill the cancer cells and help the immune system fight them.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

49 Participants Needed

ABBV-319 for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Omaha, Nebraska
This trial is testing a new drug called ABBV-319 for adults with certain blood cancers that have come back or didn't respond to treatment. The drug is given in regular intervals, starting with small amounts and gradually increasing to find the most effective amount. The goal is to see if ABBV-319 is safe and effective in reducing cancer activity.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

154 Participants Needed

Valacyclovir for Neonatal Herpes

Omaha, Nebraska
A Phase 1 study that will determine the valacyclovir dose that results in a systemic acyclovir exposure comparable to 10 mg/kg of parenterally administered acyclovir, which is an AUC0-12 of 24,000 ngxhr/mL to 48,000 ngxhr/mL. Neonates at risk of acquiring neonatal HSV will be enrolled in one of 2 cohorts. Cohort 1 will be comprised of eight subjects who will receive an initial dose of 10ml/kg of oral valacyclovir. Samples for PK assessments will be obtained to assess the exposure concentration. If the safety profile and the drug exposure concentrations in Cohort 1 are acceptable, eight new subjects will be enrolled in Cohort 2. The dose that these subjects will receive will be predicated upon the pharmacokinetic data from Cohort 1.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:1 - 2

16 Participants Needed

123456

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do clinical trials in Omaha, NE pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do clinical trials in Omaha, NE work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Omaha, NE 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Omaha, NE is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Omaha, NE several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a medical study in Omaha, NE?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest clinical trials in Omaha, NE?

Most recently, we added Deep Brain Stimulation for Parkinson's Disease, Niraparib + Temozolomide for Small Cell Lung Cancer and Physical Rehabilitation for Ankle Injury to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in Nebraska

Anxiety Clinical Trials in Nebraska

Schizophrenia Clinical Trials in Nebraska

ADHD Clinical Trials in Nebraska

Bipolar Disorder Clinical Trials in Nebraska

Multiple Sclerosis Clinical Trials in Nebraska

Autism Clinical Trials in Nebraska

Treatment Resistant Depression Clinical Trials in Nebraska

Borderline Personality Disorder Clinical Trials in Nebraska

Social Anxiety Disorder Clinical Trials in Nebraska

Parkinson's Disease Clinical Trials in Nebraska

Alzheimer's Disease Clinical Trials in Nebraska

By Location

Clinical Trials near Omaha, NE

Clinical Trials near Lincoln, NE

Clinical Trials near Kearney, NE

Clinical Trials near Grand Island, NE

Clinical Trials near Papillion, NE

Clinical Trials near Bellevue, NE

Clinical Trials near Norfolk, NE

Clinical Trials near North Platte, NE

Clinical Trials near Fremont, NE

Clinical Trials near Scottsbluff, NE

Clinical Trials near Hastings, NE

Clinical Trials near Elkhorn, NE

Other People Viewed

By Subject

13 Arthritis Trials near Omaha, NE

99 Clinical Paid Trials near Georgia

158 Clinical Paid Trials near New Orleans, LA

168 Clinical Paid Trials near Alabama

218 Clinical Trials near Bellevue, NE

41 Clinical Paid Trials near Florida

158 Clinical Paid Trials near Knoxville, TN

232 Clinical Trials near Bessemer, AL

Top Clinical Trials near Omaha, NE

Top Clinical Trials near Elkhorn, NE

Top Clinical Trials near Kearney, NE

Top Clinical Trials near Hastings, NE

By Trial

RSV Vaccine for Older Adults

Modified mRNA Vaccines for Infectious Diseases

Isatuximab Combination Therapy for Multiple Myeloma

mRNA-1273.214 Vaccine for COVID-19 in Children

Emergency Maternity Housing for Pregnant Mothers in Need

SGLT2 Inhibitors for Cystinuria

Vaccine Response After Cancer Therapy in Pediatric Patients

LY3484356 for Breast Cancer

KB707 for Lung Cancer

Diet Intervention for Human Microbiome Health

Ganciclovir for Acute Respiratory Failure

Genital Herpes Vaccine for Genital Herpes

Related Searches

Top Ic Clinical Trials

Antiviral Drugs for Long COVID

Continuous Glucose Monitoring for Metabolic Health

BMN 255 for Non-alcoholic Fatty Liver Disease

Enhanced Email Reminders for Health Maintenance

Liposomal Bupivacaine + Dexamethasone for Foot Surgery

Sphere-9 Catheter for VT

Opevesostat-Based Treatments for Prostate Cancer

Low-Dose Prednisone for Granulomatosis with Polyangiitis

Tension vs No Tension for Induction of Labor

Hypoglossal Nerve Stimulation for Sleep Apnea in Down Syndrome

Phenazopyridine for Pain After Urodynamic Testing

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial